AI/ML Innovations Inc. Completes Acquisition of Technology from Naiad Lab Inc
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) has completed its acquisition of technology from Naiad Lab Inc. The company issued 6,700,000 shares at $0.05 per share to Naiad Lab, subject to a 12-month voluntary hold period. This acquisition aligns with AIML's focus on AI and machine learning technologies in digital health and wellbeing. AIML's strategy involves partnerships and investments in companies like Health Gauge Inc. (95.2% owned), Tech2Heal (up to 22% ownership rights), AI Rx Inc. (70% owned), and NeuralCloud Solutions Inc. (100% owned). The company aims to capitalize on expanding growth areas in AI-driven healthcare management solutions and precision support delivery.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) ha completato l'acquisizione della tecnologia da Naiad Lab Inc. L'azienda ha emesso 6.700.000 azioni a $0,05 per azione a favore di Naiad Lab, soggette a un periodo di blocco volontario di 12 mesi. Questa acquisizione è in linea con il focus di AIML su tecnologie di AI e machine learning nella salute digitale e nel benessere. La strategia di AIML prevede partnership e investimenti in aziende come Health Gauge Inc. (95,2% di proprietà), Tech2Heal (fino al 22% di diritti di proprietà), AI Rx Inc. (70% di proprietà) e NeuralCloud Solutions Inc. (100% di proprietà). L'azienda mira a sfruttare aree di crescita in espansione nelle soluzioni di gestione sanitaria basate su AI e nella consegna di supporto di precisione.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) ha completado la adquisición de tecnología de Naiad Lab Inc. La compañía emitió 6.700.000 acciones a $0.05 por acción a Naiad Lab, sujeta a un período de retención voluntaria de 12 meses. Esta adquisición se alinea con el enfoque de AIML en tecnologías de AI y aprendizaje automático en salud digital y bienestar. La estrategia de AIML implica asociaciones e inversiones en empresas como Health Gauge Inc. (95,2% de propiedad), Tech2Heal (hasta un 22% de derechos de propiedad), AI Rx Inc. (70% de propiedad) y NeuralCloud Solutions Inc. (100% de propiedad). La compañía busca aprovechar áreas de crecimiento en soluciones de gestión de atención médica impulsadas por AI y entrega de soporte de precisión.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF)는 Naiad Lab Inc의 기술 인수를 완료했습니다. 이 회사는 Naiad Lab에 주당 $0.05의 가격으로 6,700,000주를 발행했으며, 12개월의 자발적 보유 기간이 적용됩니다. 이번 인수는 AIML의 디지털 건강 및 웰빙 분야의 AI 및 머신 러닝 기술에 대한 초점과 일치합니다. AIML의 전략은 Health Gauge Inc. (95.2% 소유), Tech2Heal (22%까지 소유권), AI Rx Inc. (70% 소유) 및 NeuralCloud Solutions Inc. (100% 소유)와 같은 회사들과의 파트너십 및 투자로 구성됩니다. 이 회사는 AI 기반 의료 관리 솔루션과 정밀 지원 제공의 확대되는 성장 분야를 활용할 계획입니다.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) a achevé l'acquisition de la technologie de Naiad Lab Inc. L'entreprise a émis 6.700.000 actions au prix de $0,05 par action à Naiad Lab, soumise à une période de blocage volontaire de 12 mois. Cette acquisition est en accord avec l'orientation d'AIML sur les technologies d'IA et d'apprentissage automatique dans le secteur de la santé numérique et du bien-être. La stratégie d'AIML inclut des partenariats et des investissements dans des entreprises telles que Health Gauge Inc. (95,2% de propriété), Tech2Heal (jusqu'à 22% de droits de propriété), AI Rx Inc. (70% de propriété) et NeuralCloud Solutions Inc. (100% de propriété). L'entreprise vise à tirer parti des domaines de croissance en expansion dans les solutions de gestion des soins de santé alimentées par l'IA et la livraison de support de précision.
AI/ML Innovations Inc. (CSE:AIML, OTCQB:AIMLF) hat die Übernahme von Technologie von Naiad Lab Inc. abgeschlossen. Das Unternehmen hat 6.700.000 Aktien zu je $0,05 ausgegeben und an Naiad Lab vergeben, unterliegt einer freiwilligen Haltedauer von 12 Monaten. Diese Akquisition steht im Einklang mit dem Fokus von AIML auf AI- und Machine Learning-Technologien im digitalen Gesundheits- und Wellnessbereich. Die Strategie von AIML umfasst Partnerschaften und Investitionen in Unternehmen wie Health Gauge Inc. (95,2% Eigentum), Tech2Heal (bis zu 22% Eigentumsrechte), AI Rx Inc. (70% Eigentum) und NeuralCloud Solutions Inc. (100% Eigentum). Das Unternehmen hat das Ziel, von den wachsenden Wachstumsmöglichkeiten im Bereich von AI-gesteuerten Gesundheitsmanagementlösungen und präziser Unterstützung zu profitieren.
- Acquisition of new technology from Naiad Lab Inc, potentially enhancing AIML's technological capabilities
- Strategic alignment with AI and machine learning focus in digital health sector
- Diverse portfolio of investments in AI-driven healthcare companies
- Issuance of 6,700,000 new shares, potentially diluting existing shareholders
- 12-month voluntary hold period on newly issued shares, limiting liquidity
VICTORIA, BC / ACCESSWIRE / August 23, 2024 / AI/ML Innovations Inc. ("AIML" or the "Company") (CSE:AIML)(OTCQB:AIMLF)(FWB:42FB), a leading company committed to acquiring and advancing Artificial Intelligence/Machine Learning technologies that address urgent societal needs, is pleased to announce that it has closed its previously announced acquisition of technology from Naiad Lab Inc. The Company issued a total of 6,700,000 at a deemed price of
As per the Agreement, the Common Shares issued are subject to a twelve-month voluntary hold period.
###
About AI/ML Innovations Inc. https://aiml-innovations.com/
AI/ML Innovations Inc. has realigned its business operations to capitalize on the burgeoning fields of artificial intelligence (AI) and machine learning (ML), with an initial investment focus on emerging digital health and wellbeing companies that leverage AI, ML, cloud computing and digital platforms to drive transformative healthcare management solutions and precision support delivery across the health continuum. Through strategic partnerships with Health Gauge Inc. (
On behalf of the Board of Directors
Tim Daniels, Executive Chairman
For more information about AI/ML Innovations :
For detailed information please see AI/ML's website or the Company's filed documents at www.sedarplus.ca
For further information, contact: Blake Fallis at (778) 405-0882 or info@aiml-innovations.com
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
For AI/ML Innovations Investors
Certain statements made in this press release that are not based on historical information are forward-looking statements that involve substantial known and unknown risks and uncertainties. This press release contains express or implied forward-looking statements relating to, among other things, AI/ML Innovations' expectations concerning management's plans, objectives, and strategies, including strategies for defending the Company's intellectual property. These statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. AI/ML Innovations Inc. undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events, or circumstances or otherwise except as expressly required by applicable securities law. Further information regarding the uncertainties and risks can be found in the disclosure documents filed by AI/ML with the securities regulatory authorities, available at www.sedarplus.ca
SOURCE: AI/ML Innovations, Inc.
View the original press release on accesswire.com
FAQ
What technology did AI/ML Innovations (AIMLF) acquire from Naiad Lab Inc?
How many shares did AI/ML Innovations (AIMLF) issue for the Naiad Lab acquisition?
What is the hold period for the shares issued by AI/ML Innovations (AIMLF) in the Naiad Lab deal?
What are AI/ML Innovations' (AIMLF) main investment focus areas?
